We are live on ! Find out more
INO icon

Inovio Pharmaceuticals
INO

Fund managers haven’t disclosed any holdings of INO yet.

INO Hedge Fund Activity: Q1 2026 in Review

100 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2026, worth a combined $54.6M — down 5% from $57.5M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new INO positions and 15 closed out — a net gain of 1 holder — while 19 added to existing stakes and 23 trimmed.

The largest buyer was Eversept Partners, opening a new position worth an estimated $1.7M. The largest seller was Adage Capital Partners, cutting an estimated $2.88M.

  • 100 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2026, down from 102 in Q4 2025.
  • Funds reported $54.6M of Inovio Pharmaceuticals stock for Q1 2026, down 5% quarter-over-quarter.
  • 16 funds opened new Inovio Pharmaceuticals positions in Q1 2026 and 15 closed out, a net change of +1 holder.
  • The largest Inovio Pharmaceuticals buyer in Q1 2026 was Eversept Partners, an estimated $1.7M added.
  • The largest Inovio Pharmaceuticals seller in Q1 2026 was Adage Capital Partners, an estimated $2.88M sold.

Based on aggregated 13F filings for Q1 2026.